06:30 AM EST, 11/26/2024 (MT Newswires) -- Guardant Health ( GH ) said Monday that the US District Court for the Northern District of California ruled in its favor and found that Natera ( NTRA ) engaged in false advertising and unfair competition to mislead cancer clinicians about Guardant Health's ( GH ) colorectal cancer test.

The jury rejected all of Natera's ( NTRA ) counterclaims and awarded $292.5 million to Guardant Health ( GH ), according to the statement.

Natera ( NTRA ) said it disagrees with the ruling and will ask the court to overturn its decision.

According to Natera ( NTRA ), the suit dates back to 2021 when the companies filed false advertising cases against each other over their statements about the Guardant Reveal colorectal cancer test.

"This case had nothing to do with the validity or utility of Signatera, and certain key pieces of evidence supporting Natera's ( NTRA ) case were not included in this trial," Natera ( NTRA ) said.